Field Name	Field Description
<u>Prior</u>	
<b>Authorization</b>	<u>Tzield (teplizumab-mzwv)</u>
<b>Group Description</b>	
<u>Drugs</u>	<u>Tzield (teplizumab-mzwv)</u>
<b>Covered Uses</b>	Medically accepted indications are defined using the following
	sources: the Food and Drug Administration (FDA), Micromedex,
	American Hospital Formulary Service (AHFS), United States
	Pharmacopeia Drug Information for the Healthcare Professional
	(USP DI), the Drug Package Insert (PPI), or disease state specific
	standard of care guidelines.
<b>Exclusion Criteria</b>	Type 2 diabetes (T2D)
Required Medical Information	See "Other Criteria"
Age Restrictions	A acording to pooleogo ingert
Prescriber	According to package insert
Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage	If all the criteria are met, the initial request will be approved for a
Duration	one-time treatment.
Other Criteria	**Drug is being requested through the member's medical benefit**
	<ul> <li>Initial Authorization:</li> <li>Medication is prescribed at an FDA approved dose</li> <li>Diagnosis of stage 2 type 1 diabetes (T1D) confirmed by presence of at least two of the following autoantibodies:</li> </ul>
<u>Date: 1/2023</u>	<ul> <li>Glutamic acid decarboxylase 65 (GAD) autoantibody</li> <li>Insulin autoantibody (IAA)</li> <li>Insulinoma-associated antigen 2 autoantibody (IA-2A)</li> <li>Zinc transporter 8 autoantibody (ZnT8A)</li> <li>Islet cell autoantibody (ICA)</li> <li>Abnormal glucose on an oral glucose-tolerance test (or alternative glycemic test if an oral glucose-tolerance test is not available)</li> </ul>
	If all of the above criteria are not met, the request is referred to a Medical Director/Clinical Reviewer for medical necessity review.